CoChat
Sign Up
Cited by 68

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors

Ramaraj, Pandurangan, Singh, Harjeet, Niu, Ning, Chu, Su, Holtz, Melissa, Yee, Jiing Kuan, Bhatia, Ravi·2004·Cancer Research
DOI 10.1158/0008-5472.can-03-3656
Open this paper in CoChat — free account

Abstract

Chronic myelogenous leukemia (CML) results from transformation of a primitive hematopoietic cell by the BCR/ABL gene. The specific BCR/ABL signaling mechanisms responsible for transformation of primitive human hematopoietic cells are not well defined. Previous studies have suggested that constitutively activated tyrosine kinase activity plays an important role for in abnormal proliferation of CML progenitors but has not clearly defined its role in abnormal adhesion and migration. We established a human progenitor model of CML by ectopic expression of BCR/ABL in normal CD34+ cells using retrovirus-mediated gene transfer. CD34+ cells expressing BCR/ABL demonstrated several features characteristic of primary CML progenitors including increased proliferation in committed and primitive progenitor culture, reduced adhesion to fibronectin, and reduced chemotaxis to stroma-derived factor-1α. We expressed a kinase-inactive BCR/ABL gene to directly investigate the role of kinase activity in abnormal progenitor function. Abnormalities in proliferation were completely reversed, whereas defects in adhesion and migration were significantly improved but not completely reversed in cells expressing a kinase-inactive BCR/ABL. Furthermore, the BCR/ABL kinase inhibitor imatinib mesylate markedly inhibited proliferation of BCR/ABL-expressing progenitors but did not fully correct the adhesion and migration defects. Expression of BCR/ABL genes with deletions of either the COOH-terminal actin binding or proline-rich domains resulted in enhanced adhesion and chemotaxis compared with wild-type BCR/ABL but did not affect progenitor proliferation. We conclude that abnormal kinase activity is essential for abnormal proliferation and survival of CML progenitors but that abnormal adhesion and migration result from both kinase-dependent and -independent mechanisms.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-03-3656

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 55

  1. Lugo T, Pendergast A, Muller A, Witte O Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science, 237: 1079-82, 1990. · DOI
  2. Daley GQ, Baltimore D Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic leukemia-specific P210 bcr/abl protein. Proc Natl Acad Sci USA, 85: 9312-6, 1988. · DOI
  3. Pear WS, Miller JP, Xu L, et al Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood, 92: 3780-92, 1998. · DOI
  4. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med, 189: 1399-412, 1999. · DOI
  5. Sawyers CL Chronic myeloid leukemia. N Engl J Med, 340: 1330-40, 1999. · DOI
  6. Traycoff CM, Halstead B, Rice S, McMahel J, Srour EF, Cornetta K Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. Br J Haematol, 102: 759-67, 1998. · DOI
  7. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood, 90: 64-9, 1997. · DOI
  8. Bhatia R, Munthe HA, Williams AD, Zhang F, Forman SJ, Slovak ML Increased sensitivity of chronic myelogenous leukemia primitive hematopoietic progenitors to growth factor induced cell division and maturation. Exp Hematol, 12: 1401-12, 2000. · DOI
  9. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 83: 2038-44, 1994. · DOI
  10. Maguer-Satta V, Burl S, Liu L, et al BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene, 16: 237-48, 1998. · DOI
  11. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol, 91: 387-93, 1995. · DOI
  12. Ghaffari S, Daley GQ, Lodish HF Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia, 13: 1200-6, 1999. · DOI
  13. Eaves CJ, Casman JD, Wolpe SD, Eaves AC Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci USA, 90: 12015-9, 1993. · DOI
  14. Cashman JD, Eaves CJ, Sarris AH, Eaves AC MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood, 92: 2338-44, 1998. · DOI
  15. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myelogenous leukaemia. Nature, 328: 342-4, 1984. · DOI
  16. Verfaillie CM, McCarthy JB, McGlave PB Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Investig, 90: 1232-9, 1992. · DOI
  17. Bhatia R, McCarthy JB, Verfaillie CM Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood, 87: 3883-91, 1996. · DOI
  18. Hurley RW, McCarthy JB, Verfaillie CM Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Investig, 96: 511-9, 1995. · DOI
  19. Jiang Y, Zhao RC, Verfaillie CM Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA, 97: 10538-43, 2000. · DOI
  20. Peled A, Hardan I, Trakhtenbrot L, et al Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells, 20: 259-66, 2002. · DOI
  21. Salgia R, Li J-L, Ewaniuk DS, et al BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest, 100: 46-57, 1997. · DOI · Paper page
  22. Ptasznik A, Urbanowska E, Chinta S, et al Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med, 196: 667-78, 2002. · DOI
  23. Deininger MW, Goldman JM, Melo JV The molecular biology of chronic myeloid leukemia. Blood, 96: 3343-56, 2000. · DOI
  24. Zhang X, Ren R Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood, 92: 3829-40, 1998. · DOI
  25. Zhang X, Wong R, Hao SX, Pear WS, Ren R The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood, 97: 277-87, 2001. · DOI
  26. Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, Van Etten RA The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood, 97: 4-13, 2001. · DOI
  27. He Y, Wertheim JA, Xu L, et al The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood, 99: 2957-68, 2002. · DOI
  28. Wertheim JA, Perera SA, Hammer DA, Ren R, Boettiger D, Pear WS Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood, 102: 2220-8, 2003. · DOI
  29. Druker B, Tamura S, Buchdunger E, et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2: 561-6, 1996. · DOI · Paper page
  30. Druker BJ, Talpaz M, Resta DJ, et al Efficacy and safety of a specific inhibitor of the BCR-ABL kinase in chronic myeloid leukemia. N Engl J Med, 344: 1031-7, 2001. · DOI
  31. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia cells. Anti-Cancer Drugs, 5: 213-22, 1994. · DOI
  32. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood, 79: 2215-20, 1992. · DOI
  33. Skourides PA, Perera SA, Ren R Polarized distribution of Bcr-Abl in migrating myeloid cells and co- localization of Bcr-Abl and its target proteins. Oncogene, 18: 1165-76, 1999. · DOI
  34. Heaney C, Kolibaba K, Bhat A, et al Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood, 89: 297-306, 1997. · DOI
  35. Pear WS, Nolan G, Scott M, Baltimore D Production of high titer helper free retroviruses by transient transfection. Proc Natl Acad Sci USA, 90: 8392-6, 1993. · DOI
  36. Norris PS, Jepsen K, Haas M High-titer MSCV-based retrovirus generated in the pCL acute virus packaging system confers sustained gene expression in vivo. J Virol Methods, 75: 161-7, 1998. · DOI
  37. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood, 85: 3636-45, 1995. · DOI
  38. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Investig, 94: 384-91, 1994. · DOI
  39. Bhatia R, Munthe HA, Forman SJ Abnormal growth factor modulation of β1-integrin mediated adhesion in chronic myelogenous leukemia hematopoietic progenitors. Br J Hematol, 115: 845-53, 2001. · DOI
  40. Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood, 99: 4122-30, 2002. · DOI
  41. Zhao RC, Jiang Y, Verfaillie CM A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood, 97: 2406-12, 2001. · DOI · Paper page
  42. Chalandon Y, Jiang X, Hazlewood G, et al Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood, 99: 3197-204, 2002. · DOI
  43. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene, 16: 335-48, 1998. · DOI
  44. O’Brien SG, Guilhot F, Larson RA, et al Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348: 994-1004, 2003. · DOI
  45. Bhatia R, Munthe HA, Verfaillie CM Tyrphosin AG 957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia, 12: 1708-17, 1998. · DOI
  46. Bazzoni G, Carlesso N, Griffin JD, Hemler ME Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Investig, 98: 521-8, 1996. · DOI
  47. McWhirter JR, Wang JYJ An actin-binding function contributes to transformation by the BCR-ABL oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J, 12: 1533-46, 1993. · DOI
  48. Van Etten R, Jackson P, Baltimore D, Sanders M, Matsudaira P, Janmey P The COOH terminus of c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol, 124: 325-40, 1994. · DOI
  49. McWhirter JR, Wang JY Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene, 15: 1625-34, 1997. · DOI
  50. Heisterkamp N, Voncken JW, Senadheera D, et al Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants. Blood, 96: 2226-32, 2000. · DOI
  51. Dai Z, Kerzic P, Schroeder WG, McNiece IK Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis. J Biol Chem, 276: 28954-60, 2001. · DOI
  52. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem, 269: 22925-8, 1994. · DOI
  53. Salgia R, Uemera N, Okuda K, et al CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem, 270: 29145-50, 1995. · DOI
  54. Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. Curr Biol, 11: 891-5, 2001. · DOI
  55. Bhatia R, Holtz M, Niu N, et al Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101: 4701-7, 2003. · DOI

Cited by

See all 68

Metadata

Authors
Ramaraj, P., Singh, H., Niu, N., Chu, S., Holtz, M., Yee, J. K., & Bhatia, R.
Affiliations
  • 1Hematology and Bone Marrow Transplantation and Divisions of
  • 2Virology Research, City of Hope National Medical Center, Duarte, California
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2004-08-01
Volume
64
Issue
15
Pages
5322-5331
ISSN
  • 0008-5472
  • 1538-7445
DOI
10.1158/0008-5472.can-03-3656
Cited by
68
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-3656
The paper
Ramaraj, P., Singh, H., Niu, N., Chu, S., Holtz, M., Yee, J. K., & Bhatia, R. (2004). Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-3656